NEW YORK (GenomeWeb) – Cypher Genomics has signed a co-promotion agreement with Illumina that lets the sequencing vendor offer Cypher's Coral biomarker discovery service to pharmaceutical companies.

Specifically, under the terms of the agreement, Illumina's sales force will market Coral as part of a solution to pharma that includes sequencing and its NextBio platform for data analytics and storage. Pharma firms could, for example, use the service to analyze small groups of patients in early clinical trials to discover genetic markers that are linked to therapeutic response.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The World Health Organization calls for the public release of clinical trial results within a year of the completion of data collection.

In Science this week: measles virus nucleocapsid structure, and more.

African and US health officials work to establish an Africa-wide Centres for Disease Control and Prevention.

Nature has retracted a 2002 epigenetics paper for image manipulation.

May
28
Sponsored by
PerkinElmer

This online seminar will demonstrate how RNA-seq analysis in a model organism can provide insights into human disease.